Abstract 428P
Background
Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm with an intermediate biologic potential. The aim of this study was to investigate clinical and pathological factors as well as peripheral blood counts to determine factors predicting for likelihood of early recurrence and poor survival in extra-meningeal SFTs after surgical resection.
Methods
We retrieved the records of 101 patients that were consecutively diagnosed with SFT from 1996-2019 at the National Cancer Centre Singapore and Singapore General Hospital. 19 patients were excluded from the study, of which 6 had distant metastasis at diagnosis, 5 did not undergo curative surgery and 8 were meningeal SFTs that are known to have a poor prognosis. The remaining 82 cases of extra-meningeal SFTs that underwent curative surgery were retrospectively examined with survival analyses performed using the Kaplan-Meier method and multivariate Cox proportional models.
Results
The cohort consisted of 37 men and 45 women with a median age of 51 years (range, 13-87). The primary site of the tumour was abdominopelvic in 18 (22.0%), limbs/trunk in 27 (32.9%), pulmonary/pleura in 18 (22.0%) and head/neck in 19 (23.2%). Median tumour size was 5.0 cm (range, 1.4-30.0). The 5-year overall survival (OS) and event-free survival (EFS) was 92.4% and 79.2% respectively. On univariate analysis, advanced age was prognostic for worse OS, while an abdominopelvic site, lymphocytosis (>2.2 x 109/L) and monocytosis (>0.56 x 109/L) were prognostic for both worse OS and EFS. On multivariate analysis, only age, abdominopelvic site and monocytosis remained independently prognostic for OS, while abdominopelvic site and monocytosis were retained as independently prognostic factors for EFS (all p < 0.05). Tumour depth, tumour size, resection margin, tumour necrosis and mitotic count were not significantly prognostic.
Conclusions
In extra-meningeal SFT, clinical factors including advanced age and abdominopelvic location indicate poor prognosis. In addition, peripheral monocytosis at diagnosis may serve as a novel and easily obtained biomarker for further prognostication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session